The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard?
 
Jonas C. S. Bergh
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
Other Relationship - UpToDate
 
Anne Andersson
No Relationships to Disclose
 
Judith Bjohle
No Relationships to Disclose
 
Ana Bosch
Consulting or Advisory Role - Roche
Travel, Accommodations, Expenses - Pfizer; Roche
 
Lena Carlsson
No Relationships to Disclose
 
Ann Charlotte Dreifaldt
No Relationships to Disclose
 
Zakaria Einbeigi
No Relationships to Disclose
 
Hanna Fredholm
No Relationships to Disclose
 
Erika Isaksson-Friman
Research Funding - Novartis (Inst)
 
Theodoros Foukakis
Honoraria - UpToDate
Research Funding - Pfizer (Inst)
 
Ellinor Elinder
No Relationships to Disclose
 
Mats Hellstrom
No Relationships to Disclose
 
Hemming Johansson
No Relationships to Disclose
 
Tobias Lekberg
No Relationships to Disclose
 
Henrik Lindman
Consulting or Advisory Role - AstraZeneca; Novartis; Pfizer
Research Funding - Roche (Inst)
 
Claudia Maes
No Relationships to Disclose
 
Yvonne Brandberg
No Relationships to Disclose
 
Thomas Hatschek
Consulting or Advisory Role - Pfizer (Inst)
Research Funding - Pfizer (Inst); Roche (Inst)